Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 267

Sponsor: University of Maryland, Baltimore

Summary

Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of developing kidney damage after heart surgery. There is evidence that patients with high levels of a substance called ouabain have an increased risk of developing kidney damage. This study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain levels will reduce the risk of developing kidney damage after heart surgery.

Eligibility Criteria

Inclusion Criteria: * Undergoing coronary artery bypass surgery * glomerular filtration rate \> 15 History of Diabetes Mellitus or GFR \< 60 Exclusion Criteria: * Allergy to Digifab Contrast dye within 3 days Creatinine \> 25% above baseline

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT03810417). StuddyBuddy aggregates publicly available trial information.